Abstract: Provided herein are modified immunoglobulins comprising an amyloid reactive peptide joined to an antibody, as well as humanized antibodies that bind to human amyloid fibrils and antibody-peptide fusion proteins. Also provided herein are methods of treating amyloid-based diseases by administering a modified immunoglobulin, humanized antibody, or antibody-peptide fusion protein.
Type:
Grant
Filed:
May 9, 2024
Date of Patent:
April 1, 2025
Assignees:
Attralus, Inc, University of Tennessee Research Foundation
Inventors:
Jonathan S. Wall, James S. Foster, Spencer Guthrie
Abstract: The present invention relates to SAP-Fc fusion proteins comprising one or more amino acid substitution, for example, C226S and/or C229S. In some aspects, the fusion protein comprises a structure represented by the following formula, from N-terminus to C-terminus, SAP-Fc1-L1-Fc2, wherein Fc1 is a first Fc domain sequence comprising hinge-CH2-CH3, L1 is a linker, and Fc2 is a second Fc domain sequence comprising hinge-CH2-CH3. The present invention also relates to methods of treating amyloid related diseases by administering said SAP-Fc fusion proteins to a subject in need thereof.
Type:
Grant
Filed:
November 1, 2021
Date of Patent:
December 10, 2024
Assignees:
Attralus, Inc., UNIVERSITY OF TENNESSEE RESSEARCH FOUNDATION
Abstract: Provided herein are modified immunoglobulins comprising an amyloid reactive peptide joined to an antibody, as well as humanized antibodies that bind to human amyloid fibrils and antibody-peptide fusion proteins. Also provided herein are methods of treating amyloid-based diseases by administering a modified immunoglobulin, humanized antibody, or antibody-peptide fusion protein.
Type:
Grant
Filed:
May 9, 2024
Date of Patent:
December 3, 2024
Assignees:
Attralus, Inc., UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION
Inventors:
Jonathan S. Wall, James S. Foster, Spencer Guthrie
Abstract: Provided herein are modified immunoglobulins comprising an amyloid reactive peptide joined to an antibody, as well as humanized antibodies that bind to human amyloid fibrils and antibody-peptide fusion proteins. Also provided herein are methods of treating amyloid-based diseases by administering a modified immunoglobulin, humanized antibody, or antibody-peptide fusion protein.
Type:
Grant
Filed:
March 9, 2023
Date of Patent:
July 9, 2024
Assignees:
Attralus, Inc., UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION
Inventors:
Jonathan S. Wall, James S. Foster, Spencer Guthrie
Abstract: Provided herein are amyloid-reactive peptide-Fc fusion proteins comprising an amyloid-reactive peptide linked to a human Fc region. Also provided herein are methods of treating amyloid-based diseases and identifying amyloid deposits by administering an amyloid-reactive peptide-Fc fusion protein comprising an amyloid-reactive peptide linked to a human Fc region.
Type:
Application
Filed:
May 4, 2022
Publication date:
July 4, 2024
Applicants:
UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION, Attralus, Inc.
Inventors:
Jonathan S. WALL, James S. FOSTER, Jaume PONS